|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Blumenschein GR Jr, Mills GB and
Gonzalez-Angulo AM: Targeting the hepatocyte growth factor-cMET
axis in cancer therapy. J Clin Oncol. 30:3287–3296. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim YJ, Go H, Wu HG, Jeon YK, Park SW and
Lee SH: Immunohistochemical study identifying prognostic
biomolecular markers in nasopharyngeal carcinoma treated by
radiotherapy. Head Neck. 33:1458–1466. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Raghav KP, Wang W, Liu S, Chavez-MacGregor
M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein
GR Jr and Gonzalez-Angulo AM: cMET and phospho-cMET protein levels
in breast cancers and survival outcomes. Clin Cancer Res.
18:2269–2277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Preusser M, Streubel B, Berghoff AS,
Hainfellner JA, von Deimling A, Widhalm G, Dieckmann K, Wöhrer A,
Hackl M, Zielinski C and Birner P: Amplification and overexpression
of CMET is a common event in brain metastases of non-small cell
lung cancer. Histopathology. 65:684–692. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bhardwaj V, Cascone T, Cortez MA, Amini A,
Evans J, Komaki RU, Heymach JV and Welsh JW: Modulation of c-Met
signaling and cellular sensitivity to radiation: Potential
implications for therapy. Cancer. 119:1768–1775. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Firtina Karagonlar Z, Koc D, Iscan E,
Erdal E and Atabey N: Elevated hepatocyte growth factor expression
as an autocrine c-Met activation mechanism in acquired resistance
to sorafenib in hepatocellular carcinoma cells. Cancer Sci.
107:407–416. 2007. View Article : Google Scholar
|
|
11
|
Xie LQ, Bian LJ, Li Z, Li Y and Liang YJ:
Co-elevated expression of hepatocyte growth factor and
Interleukin-8 contributes to poor prognosis of patients with
primary nasopharyngeal carcinoma. Oncol Rep. 23:141–150.
2010.PubMed/NCBI
|
|
12
|
Sipos F, Galamb O, Herszényi L, Molnár B,
Solymosi N, Zágoni T, Berczi L and Tulassay Z: Elevated
insulin-like growth factor 1 receptor, hepatocyte growth factor
receptor and telomerase protein expression in mild ulcerative
colitis. Scand J Gastroenterol. 43:289–298. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Okazaki M, Yoshimura K, Uchida G and Harii
K: Elevated expression of hepatocyte and keratinocyte growth factor
in cultured buccal-mucosa-derived fibroblasts compared with
normal-skin-derived fibroblasts. J Dermatol Sci. 30:108–115. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Y, Li M, Zhang G and Pang Z:
MicroRNA-10b overexpression promotes non-small cell lung cancer
cell proliferation and invasion. Eur J Med Res. 18:412013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM
and Zhang GZ: Biological functions of microRNAs: A review. J
Physiol Biochem. 67:129–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lages E, Ipas H, Guttin A, Nesr H, Berger
F and Issartel JP: MicroRNAs: Molecular features and role in
cancer. Front Biosci (Landmark Ed). 17:2508–2540. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kasinski AL and Slack FJ: Epigenetics and
genetics. MicroRNAs en route to the clinic: Progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Tan Q, Yan M, Liu L, Lin H, Zhao F,
Bao G, Kong H, Ge C, Zhang F, et al: miRNA-200c inhibits invasion
and metastasis of human non-small cell lung cancer by directly
targeting ubiquitin specific peptidase 25. Mol Cancer. 13:1662014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu T, Li J, Yan M, Liu L, Lin H, Zhao F,
Sun L, Zhang Y, Cui Y, Zhang F, et al: MicroRNA-193a-3p and −5p
suppress the metastasis of human non-small-cell lung cancer by
downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway.
Oncogene. 34:413–423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang R, Chen DQ, Huang JY, Zhang K, Feng
B, Pan BZ, Chen J, De W and Chen LB: Acquisition of radioresistance
in docetaxel-resistant human lung adenocarcinoma cells is linked
with dysregulation of miR-451/c-Myc-survivin/rad-51 signaling.
Oncotarget. 5:6113–6129. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Montoya V, Fan H, Bryar PJ, Weinstein JL,
Mets MB, Feng G, Martin J, Martin A, Jiang H and Laurie NA: Novel
miRNA-31 and miRNA-200a-mediated regulation of retinoblastoma
proliferation. PLoS One. 10:e01383662015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang JJ, Tao H, Hu W, Liu LP, Shi KH, Deng
ZY and Li J: MicroRNA-200a controls Nrf2 activation by target Keap1
in hepatic stellate cell proliferation and fibrosis. Cell Signal.
26:2381–2389. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu YY, Chen MB, Cheng L, Zhang ZQ, Yu ZQ,
Jiang Q, Chen G and Cao C: microRNA-200a downregulation in human
glioma leads to Gαi1 over-expression, Akt activation, and cell
proliferation. Oncogene. 37:2890–2902. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Blum D and LaBarge S: Reproducibility
Project: Cancer Biology: Registered report: Tumour
micro-environment elicits innate resistance to RAF inhibitors
through HGF secretion. Elife. 3:e040342014.doi:10.7554/eLife.04034.
View Article : Google Scholar :
|
|
29
|
Rivera M, Sukhdeo K and Yu J: Ionizing
radiation in glioblastoma initiating cells. Front Oncol. 3:742013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
De Bacco F, Luraghi P, Medico E, Reato G,
Girolami F, Perera T, Gabriele P, Comoglio PM and Boccaccio C:
Induction of MET by ionizing radiation and its role in
radioresistance and invasive growth of cancer. J Natl Cancer Inst.
103:645–661. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Veenstra C, Pérez-Tenorio G, Stelling A,
Karlsson E, Mirwani SM, Nordensköljd B, Fornander T and Stål O: Met
and its ligand HGF are associated with clinical outcome in breast
cancer. Oncotarget. 7:37145–37159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Saigusa S, Toiyama Y, Tanaka K, Yokoe T,
Fujikawa H, Matsushita K, Okugawa Y, Inoue Y, Uchida K, Mohri Y and
Kusunoki M: Inhibition of HGF/cMET expression prevents distant
recurrence of rectal cancer after preoperative chemoradiotherapy.
Int J Oncol. 40:583–591. 2012.PubMed/NCBI
|
|
33
|
Hosoda H, Izumi H, Tukada Y, Takagiwa J,
Chiaki T, Yano M and Arai H: Plasma hepatocyte growth factor
elevation may be associated with early metastatic disease in
primary lung cancer patients. Ann Thorac Cardiovasc Surg. 18:1–7.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Navab R, Liu J, Seiden-Long I, Shih W, Li
M, Bandarchi B, Chen Y, Lau D, Zu YF, Cescon D, et al:
Co-overexpression of Met and hepatocyte growth factor promotes
systemic metastasis in NCI-H460 non-small cell lung carcinoma
cells. Neoplasia. 11:1292–1300. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen Y, Du M, Wang J, Xing P, Zhang Y, Li
F and Lu X: MiRNA-200a expression is inverse correlation with
hepatocyte growth factor expression in stromal fibroblasts and its
high expression predicts a good prognosis in patients with
non-small cell lung cancer. Oncotarget. 7:48432–48442.
2016.PubMed/NCBI
|
|
36
|
Jankowski K, Kucia M, Wysoczynski M, Reca
R, Zhao D, Trzyna E, Trent J, Peiper S, Zembala M, Ratajczak J, et
al: Both hepatocyte growth factor (HGF) and stromal-derived
factor-1 regulate the metastatic behavior of human rhabdomyosarcoma
cells, but only HGF enhances their resistance to radiochemotherapy.
Cancer Res. 63:7926–7935. 2003.PubMed/NCBI
|
|
37
|
Sylvester PW: Targeting met mediated
epithelial-mesenchymal transition in the treatment of breast
cancer. Clin Transl Med. 3:302014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kou J, Musich PR, Staal B, Kang L, Qin Y,
Yao ZQ, Zhang B, Wu W, Tam A, Huang A, et al: Differential
responses of MET activations to MET kinase inhibitor and
neutralizing antibody. J Transl Med. 16:2532018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cruickshanks N, Zhang Y, Hine S, Gibert M,
Yuan F, Oxford M, Grello CM, Pahuski M, Dube C, Guessous F, et al:
Discovery and therapeutic exploitation of mechanisms of resistance
to MET inhibitors in glioblastoma. Clin Cancer Res. September
10–2018.(Epub ahead of print). doi: 10.1158/1078-0432.CCR-18-0926.
PubMed/NCBI
|
|
40
|
Aliebrahimi S, Montasser Kouhsari S, Ostad
SN, Arab SS and Karami L: Identification of phytochemicals
targeting c-Met kinase domain using consensus docking and molecular
dynamics simulation studies. Cell Biochem Biophys. 76:135–145.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu X, Kou J, Xiao Z, Tian F, Hu J, Zheng
P and Zhu W: Design, synthesis and biological evaluation of
6,7-disubstituted-4-phenoxyquinoline derivatives bearing
pyridazinone moiety as c-Met inhibitors. Molecules. 23:E15432018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Harshman LC and Choueiri TK: Targeting the
hepatocyte growth factor/c-Met signaling pathway in renal cell
carcinoma. Cancer J. 19:316–323. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Peters S and Adjei AA: MET: A promising
anticancer therapeutic target. Nat Rev Clin Oncol. 9:314–326. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Utsugi T: New challenges and inspired
answers for anticancer drug discovery and development. Jpn J Clin
Oncol. 43:945–953. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Redis RS, Berindan-Neagoe I, Pop VI and
Calin GA: Non-coding RNAs as theranostics in human cancers. J Cell
Biochem. 113:1451–1459. 2012.PubMed/NCBI
|
|
46
|
Cherni I and Weiss GJ: miRNAs in lung
cancer: Large roles for small players. Future Oncol. 7:1045–1055.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Du L and Pertsemlidis A: microRNA
regulation of cell viability and drug sensitivity in lung cancer.
Expert Opin Biol Ther. 12:1221–1239. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mateescu B, Batista L, Cardon M, Gruosso
T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P,
Sastre-Garau X and Mechta-Grigoriou F: miR-141 and miR-200a act on
ovarian tumorigenesis by controlling oxidative stress response. Nat
Med. 17:1627–1635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang X and Li GH: MicroRNA-16 functions as
a tumor-suppressor gene in oral squamous cell carcinoma by
targeting AKT3 and BCL2L2. J Cell Physiol. 233:9447–9457. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sun GL, Li Z, Wang WZ, Chen Z, Zhang L, Li
Q, Wei S, Li BW, Xu JH, Chen L, et al: miR-324-3p promotes gastric
cancer development by activating Smad4-mediated Wnt/beta-catenin
signaling pathway. J Gastroenterol. 53:725–739. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cortez MA, Valdecanas D, Zhang X, Zhan Y,
Bhardwaj V, Calin GA, Komaki R, Giri DK, Quini CC, Wolfe T, et al:
Therapeutic delivery of miR-200c enhances radiosensitivity in lung
cancer. Mol Ther. 22:1494–1503. 2014. View Article : Google Scholar : PubMed/NCBI
|
